Session Details

Session Details

08:00 AM - 09:45 AM - Ballroom 2

Manish Muhuri - PhD -

Co-Chair

08:00 AM - 08:15 AM - Ballroom 2

Elizabeth Kropf - Spark Therapeutics

352: C3 Complement Inhibitor Limits Transaminitis and Immune Response Following Liver Targeted Adeno-Associated Virus (AAV) Gene Transfer (GT) in Non-Human Primates (NHPs)

08:00 AM - 09:45 AM - Ballroom 2

Helena Costa Verdera - PhD - Spark Therapeutics

Co-Chair

08:15 AM - 08:30 AM - Ballroom 2

Nicholas Giovannone - PhD - Regeneron Pharmaceuticals

353: Orthogonal B Cell and Plasma Cell Immunosuppression Strategies Prevent and Suppress High-Titer Antibody Immunity to Enable AAV Vector Re-Dosing

08:30 AM - 08:45 AM - Ballroom 2

Maria Gioulvanidou - Weill Cornell Medical College

354: Vectorized Antibody-Mediated Anti-Eosinophil Gene Therapy

08:45 AM - 09:00 AM - Ballroom 2

Shari Gordon - Asklepios BioPharmaceutical, Inc.

355: Modulating the AAV-Specific Immune Response: A Comparison of T Cell Co-Stimulation Blockade with Rapamycin Plus B Cell Depletion

09:00 AM - 09:15 AM - Ballroom 2

Elena Campbell - PhD - University of Guelph

356: Vectorized Expression of a Pan-Filovirus Bispecific Monoclonal Antibody in a Murine Model for Protection Against Ebola and Marburg Virus Challenge

09:15 AM - 09:30 AM - Ballroom 2

Saghana Muraleetharan - MS - Spark Therapeutics

357: Evaluating the Effects of IdeS-Generated Anti-AAV IgG Fragments on AAV Gene Delivery

09:30 AM - 09:45 AM - Ballroom 2

Blake Rust - PhD - Asklepios BioPharmaceutical, Inc.

358: IgG Enzymatic Cleavage Prevents Uptake of AAV and Activation of Phagocytic Immune Cells in Seropositive Human Donors